Clorox (NYSE:CLX) Price Target Raised to $114.00

Clorox (NYSE:CLX) had its target price raised by equities research analysts at Deutsche Bank Aktiengesellschaft from $110.00 to $114.00 in a research note issued to investors on Friday,MarketScreener reports. The brokerage presently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential downside of 0.66% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. BNP Paribas Exane cut their price target on shares of Clorox from $103.00 to $101.00 and set an “underperform” rating for the company in a research note on Friday, January 16th. Barclays restated an “underweight” rating and set a $109.00 target price on shares of Clorox in a research report on Friday, January 16th. Rothschild & Co Redburn lowered their price target on Clorox from $120.00 to $115.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. The Goldman Sachs Group reduced their target price on shares of Clorox from $110.00 to $94.00 and set a “sell” rating on the stock in a research note on Wednesday, January 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $152.00 target price on shares of Clorox in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Buy rating, thirteen have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $122.19.

Clorox Stock Performance

Shares of CLX traded up $2.56 on Friday, reaching $114.76. 336,733 shares of the stock traded hands, compared to its average volume of 2,104,360. The stock’s 50-day moving average price is $103.60 and its 200-day moving average price is $114.94. The company has a debt-to-equity ratio of 18.01, a current ratio of 0.76 and a quick ratio of 0.50. The firm has a market cap of $14.00 billion, a price-to-earnings ratio of 18.04, a P/E/G ratio of 0.55 and a beta of 0.58. Clorox has a 12 month low of $96.66 and a 12 month high of $164.22.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.07. Clorox had a net margin of 11.68% and a return on equity of 358.39%. The company had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.41 billion. During the same quarter in the prior year, the company posted $1.86 EPS. The business’s revenue was down 18.9% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. Equities analysts forecast that Clorox will post 7.15 EPS for the current fiscal year.

Insider Activity

In other news, Director Pierre R. Breber purchased 4,000 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The shares were acquired at an average price of $104.13 per share, for a total transaction of $416,520.00. Following the completion of the acquisition, the director directly owned 13,000 shares in the company, valued at approximately $1,353,690. The trade was a 44.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.63% of the stock is owned by company insiders.

Institutional Investors Weigh In On Clorox

Institutional investors have recently modified their holdings of the business. Center for Financial Planning Inc. acquired a new position in Clorox in the third quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of Clorox in the 3rd quarter worth $25,000. Total Investment Management Inc. acquired a new stake in shares of Clorox during the second quarter worth $25,000. American National Bank & Trust increased its holdings in Clorox by 69.5% in the second quarter. American National Bank & Trust now owns 217 shares of the company’s stock valued at $26,000 after purchasing an additional 89 shares during the last quarter. Finally, True Wealth Design LLC boosted its holdings in Clorox by 1,020.0% during the third quarter. True Wealth Design LLC now owns 224 shares of the company’s stock worth $28,000 after buying an additional 204 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Key Stories Impacting Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox agreed to acquire GOJO Industries, maker of Purell, for $2.25 billion in cash; management says the deal is growth‑accretive, expands Clorox’s health & hygiene portfolio and supports its IGNITE strategy to deliver more consistent, profitable growth. Clorox Announces Acquisition of GOJO Industries, Makers of Purell®
• Positive Sentiment: Company frames GOJO as complementary — Purell’s consumer and large B2B installed base (dispensers) offers cross‑sell and distribution leverage to accelerate growth of both consumer and professional channels. Analysts note potential recurring revenue from dispenser installs and refills. Clorox to Buy Purell-Maker Gojo for $2.25 Billion
• Positive Sentiment: Clorox nudged FY‑2026 EPS guidance to $5.95–$6.30 (vs. consensus ~5.91), signaling management confidence in near‑term earnings despite the M&A spend; revenue guidance was broadly in line with consensus. (Guidance disclosure summarized by company updates and reports.)
• Neutral Sentiment: Management held an M&A call and provided slide materials and a transcript outlining strategic rationale and integration plans; useful for tracking projected synergies and timing. The Clorox Company (CLX) GOJO Industries, Inc., – M&A Call – Slideshow
• Neutral Sentiment: Full call transcript is available for investors who want detail on purchase accounting, integration staffing and channel overlap; these will determine the timeline for any accretion. The Clorox Company (CLX) M&A Call Transcript
• Negative Sentiment: The deal is being funded with debt and, although the company cites ~ $330M of tax benefits that lower the net purchase price, the cash outlay and added leverage raise balance‑sheet and interest‑coverage risks that investors should monitor. Clorox Announces Acquisition of GOJO Industries, Makers of Purell(R)
• Negative Sentiment: Some sell‑side skepticism persists: Barclays kept an Underweight/“Sell” stance (though with a slightly higher target), highlighting ongoing fundamentals concerns; expect continued analyst scrutiny on margins, private‑label pressure and execution risk. Barclays Remains a Sell on Clorox (CLX)
• Negative Sentiment: Near‑term top‑line risk persists: commentary and previews flagged continued private‑label competition in household categories, which could pressure organic growth independent of the GOJO deal. Clorox Q2 Preview: Private Label Pressure Clouds The Outlook

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.